Head-to-head · WeighScore
AgelessRx vs Oak
By GLP-1 ScorecardUpdated
Score comparison
AgelessRx has the higher recorded score — 84.3/100 to 63.2/100.
AgelessRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Conventional and microdose GLP-1 programs with continuing care; branded prescriptions involve a separate pharmacy payment.
Before you choose
AgelessRx does not publish a semaglutide price, so its AgelessRx review sets out what it does disclose, while the Oak review explains the conditions attached to Oak's figure. The semaglutide cost page compares published rates across the field. Ask AgelessRx for a written total before treating either one as the cheaper choice.
If neither one fits, AgelessRx vs Ondra Health and CoreAge Rx vs Oak compare each of them with another graded program, and the list of alternatives to AgelessRx ranks the programs closest to AgelessRx on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | AgelessRx | Oak |
|---|---|---|
| WeighScore | 84.3/100 | 63.2/100 |
| Grade | B | C |
| Site position | #17 | #213 |
| Semaglutide | Not verified (current medication-specific quote required) | From $119/mo on a 12-month plan; quarterly or upfront billing depends on selected plan; actual dose, supply and charge unverified |
| Tirzepatide | Microdose: $109 first month, then $318 every 2 months ($159/mo); full-dose quote required | From $185/mo on a 12-month plan; quarterly or upfront billing depends on selected plan; actual dose, supply and charge unverified |
| Coverage | Advertises US service; confirm treatment-specific state availability | Confirm selected treatment and state: homepage promotes a 50-state provider network, while terms say 45 states or certain states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Site position #17 · B
Strengths
- Conventional and lower-dose GLP-1 programs advertised
- Wegovy pens and oral-tablet consultations advertised
- Continuing messaging and check-ins advertised
What to consider
- Conventional medication-specific monthly quotes not verified
- Microdose introduction renews as a two-month charge
- Branded medication has a separate pharmacy bill
- Treatment-specific state eligibility and assigned dispenser need confirmation
Strengths
- Current semaglutide and tirzepatide product pages explicitly identify the twelve-month term behind advertised starting rates
- Monthly and three-month plans have no cancellation fee before the next charge under the current refund section
- The policy specifies a medical-stop exception, prepaid future-month refund calculation and a limit on quarterly-plan discount repayment
- Branded pens and Oral Wegovy tablets are now advertised alongside compounded injections; availability and exact prices require confirmation
What to consider
- The $119/$185 rates do not establish a monthly debit, dose-independent price or usable shipment supply
- Leaving a six- or twelve-month quarterly plan early can repay discounts on months received, capped at one quarterly payment
- Orders already sent to the pharmacy are final; stopping the account does not refund them
- The same terms page retains inconsistent company names, membership-fee language and state-availability statements
- The public material reviewed did not establish the assigned medical practice, individual prescriber or dispensing pharmacy legal name and address
Featured provider
Oak
Factor scores not reassessed.Oak scores 63.2/100 (C). Oak advertises compounded semaglutide from $119 and tirzepatide from $185 per month on twelve-month plans; compare the actual payment schedule and discount repayment terms before choosing a longer commitment.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.